BRIDGEBIO PHARMA, INC.

BRIDGEBIO PHARMA, INC. filed a Q4 report for BRIDGEBIO PHARMA, INC. on January 20, 2026.

Lobbying for BRIDGEBIO PHARMA, INC. · Biotech company

All filings by BRIDGEBIO PHARMA, INC. · Everything BRIDGEBIO PHARMA, INC. has reported

Amended

The filer submitted a later report covering this same period, so the amounts here have been replaced. Site totals count only the latest version. See the current filing, posted Jul 17, 2026.

Filing · LD-2 quarterly report Q4 report

Reporting period

4th Quarter 2025

Oct 1 - Dec 31 · Posted Jan 20, 2026

Expenses

$270,000

What this organization spent lobbying with its own staff. Reported using the LDA's own definitions (method A): the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.

Client based in

California

Official filing document

Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 1

Pharmacy

Give Kids a Chance Act of 2025 - H.R. 1262; S 932 General issues and provisions related to PBM Reform ORPHAN Cures Act - included in H.R. 1 - One Big Beautiful Bill Act Orphan drug policies

Bills named in this filing 2

H.R. 1262
Mikaela Naylon Give Kids a Chance Act
H.R. 1
One Big Beautiful Bill Act

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.